Along these lines, a recent evaluation of the CAD antihistamine clemastine reported LMP-mediated death of patient-derived glioblastoma cells but minimal cytotoxicity in normal human astrocytes [71], indicating a therapeutic window for treatment of this aggressive and lethal disease not unlike that observed in our HMA studies. The gene discussed is PDLIM7; the disease is glioblastoma.